Brean Murray

Brean Murray has lowered the price target on Bally Technology (NYSE: BYI) from $51 to $43 and maintains its Buy rating.

Brean Murray is out with a research report on New York & Company, Inc. (NYSE: NWY) and is lowering the price target from $6 to $5.50, and it has a Buy rating on shares. In a note to clients, Brean Murray writes, "We are reiterating our Buy rating and adjusting our target price to $5.50 from...

Brean Murray cites Penn National National Gaming's (NASDAQ: PENN) strong Q2 results, improved margins, management's ability to build shareholder value, and an aggressive expansion pipeline.

Brean Murray, Carret & Co. has published a report on Xerox (NYSE: XRX). In the report, Brean Murray, Carrent & Co. wrote, "We expect essentially in-line revenue and EPS results for the Jun Q, although we could envision upside to Street of $0.24 (XRX guidance was $0.23 - $0.26.) A bit...

Brean Murray, Carret & Co., which initiated InterMune Inc. (NASDAQ: ITMN) at Buy, is providing some color on the stock. “We are initiating coverage of InterMune with a Buy rating and a $50 price target,” Brean Murray writes. “InterMune is beginning to launch Esbriet, a newly approved drug for...

Brean Murray is out with a research report on Walter Energy (NYSE: WLT), as the company's CEO unexpectedly resigned yesterday. It has a Buy rating and a $156 price target on shares. Shares of WLT are down 95 cents in pre-market trading to $114.85, a loss of 0.82%.

Brean Murray is raising its price target on shares of Bally Technologies (NYSE: BYI) to $51 from $48, and it has a Buy rating on shares. Shares of BYI gained 35 cents yesterday to close at $40.68, a gain of nearly 1%.

Pre-open movers US stock futures are lower this morning, as investors are awaiting the start of Apple Inc's (NASDAQ: AAPL) annual developers conference. Futures on the Dow Jones Industrial Average dropped 30 points to 12,095.00 and futures on the S&P 500 stock index fell 3.10 points to 1,293.20...

In a report focusing on Pitney Bowes Inc. (NYSE: PBI), Brean Murray reports that the company had a “solid in-line Mar Q and reiteration of 2011 guidance” that left “us feeling the year is off to a solid start.” “Revenue and EPS of $1.3 and $0.53 was in-line with the Street, and PBI reiterated its...

Brean Murray is raising its PT on shares of Arrow Electronics, Inc. (NYSE: ARW) from $48 To $55. Arrow Electronics closed Wednesday at $45.63.

Brean Murray is raising its PT on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) from $67 from $78. Regeneron Pharmaceuticals closed Wednesday at $67.05.

Brean Murray is raising its FY2012 EPS estimate on shares of Iconix Brand Group, Inc. (NASDAQ: ICON) from $1.67 to $1.81. Iconix closed Wednesday at $23.28.

Nektar Therapeutics (NASDAQ: NKTR) reported 1Q11 revenue of $11.3 million and EPS of $(0.33), “both of which are below consensus of $17.2 and $(0.27), but neither truly matter at this point in Nektar's development,” Brean Murray reports. Nektar Therapeutics closed Wednesday at $9.96.